A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Research article published in Journal of thrombosis and thrombolysis (2014)
Abstract
The use of novel anticoagulants such as dabigatran are increasing. Despite increased risks of intracerebral haemorrhage with warfarin among Asians, there is little published data on dabigatran to assess 'real world' efficacy and safety of dabigatran therapy in Asia. This was a retrospective observational study of patients prescribed dabigatran between 2010 and 2013. Data was available for 510 patients: median age 68 years (range 20-91), median CHA2DS2-VASc score was 2 and median HAS-BLED score was 2. The average follow-up duration of 315 days (range: 1-1,096). The overall discontinuation rate was 16% after a median 252 days of treatment with dabigatran. There were 17 (3.3%) patients with minor bleeding, 2 (0.4%) had major bleeding episodes. 20 patients (3.9%) developed dyspepsia which was the most common side effect. The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial. None of the patients had an ischaemic stroke, 1 (0.2%) patient had a haemorrhagic stroke. Out of 510 patients, 158 patients (31%) were switched to dabigatran from warfarin. This showed that patients frequently preferred the dabigatran due to convenience when given a choice to switch from warfarin. We report one of the largest registry of Asian patients. Reassuringly, we found that our cohort had a low rate of rate of ischaemic stroke, low rates of side effects and bleeding with the drug.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Por qué esto importa para la hirudoterapia
Este estudio observacional retrospectivo reporta la experiencia en el mundo real con dabigatrán en 510 pacientes (mediana de edad de 68 años) a quienes se les prescribió el fármaco entre 2010 y 2013, con una duración media del seguimiento de 315 días. El estudio no encontró accidentes cerebrovasculares isquémicos, registró bajas tasas de hemorragia mayor (0,4%), una tasa de discontinuación del 16% y la dispepsia como efecto adverso más frecuente (3,9%). Aunque el dabigatrán es un inhibidor directo de la trombina y el artículo está indexado bajo "Antitrombinas" en MeSH, el resumen no menciona las sanguijuelas, la hirudoterapia ni los compuestos derivados de la sanguijuela. El estudio se centra por completo en los resultados de la anticoagulación farmacológica, y su pertinencia al ámbito de ASH es insignificante, sin ninguna conexión defendible con la sanguijuela.
Citación
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Yap et al. · Journal of thrombosis and thrombolysis, 2014
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026